Bespoke Digital Events Theatre


9 December 2020
10:00 – 11:00 Singapore Standard Time (SGT)
Click here to view in your timezone >>

Virtual: The New Norm For Trials?

Virtual and telemedicine technology adoption in healthcare and clinical trials is still in its infancy, and the impact of the COVID-19 will remain long after this pandemic.

According to a recent survey by Sage Growth Partners and Black Book Market Research, 33% of patients would consider leaving their current physician for one that offered telehealth access. This rise in telehealth popularity is not only patient-centric; it also reduces the spread of infectious diseases and provides greater patient healthcare access and opens the door to virtual clinical trials.

This webinar brings together a tech showcase, and pharma experts’ insights on where we are today with virtual, digital and patient-centric technologies in clinical trials. Key discussion points include:

  • How do Sponsors like Moderna running mega global trials strategize around digital for vaccine and therapeutic development in a Covid-19 pandemic?
  • How do healthcare leaders at Scripps Health leverage digital technologies and innovation in practice and clinical trials before and after Covid-19 pandemic?
  • What is the cost of technology adoption?
  • What key bottlenecks and technology gaps still exist for clinical research?

Tech Showcase:

Harsha K Rajasimha
Founder & CEO, Jeeva Informatics Solutions

Driven by a personal cause in 2012, Harsha decided to apply his years of post-doctoral experience in genomics data science and precision medicine at the National Institutes of Health and industry product development experience towards accelerating the development of diagnostics and therapies for rare diseases.

Harsha is the author of  15 high impact journal publications, book chapters and inventor on patents. He is often a keynote speaker, convener of #DigitalOMICS meetups around the Capital Beltway and part of numerous conference organizing committees.  Harsha has received numerous Awards for his work in genomics, precision medicine and rare diseases including; a travel award to join the NGO Committee on Rare Diseases at the United Nations New York headquarters in Feb 2019, Lead India Foundation 2020 Award for leadership and outstanding achievement in rare diseases, NTT DATA Healthcare Life Sciences Silver award for outstanding achievement 2017, Sanofi Genzyme patient advocacy leadership award 2016, Bioscience company of the year 2014, NEI director’s innovation award 2012 for building their genomics cyber infrastructure.  Harsha earned his M.S. in Computer Science (2004) and Ph.D. in Genetics, Bioinformatics and Computational Biology (2007) from Virginia Tech.

Veer Mehta
Founder, Halo Health

Veer Mehta is the founder and CEO at Halo Health Systems, a digital platform that accelerates clinical trials for pharma. With over 15 years of medical industry experience, he has extensive experience in the development & launch of FDA approved medical devices and digital health solutions. Veer has led engineering teams that have worked closely with large medical device and pharma companies, developing innovative technologies in the areas of endocrinology, cardiology, and immunology therapeutics. His passion for improving patient centricity in healthcare has led to an accomplished career in medical technologies, improving the lives of patients, clinicians, and researchers.

Pharma Perspective:

Jean-Rémy Behaeghel
Sr Director, Clinical Informatics, Moderna

Jean-Remy Behaeghel is the Sr Director for Clinical Informatics at Moderna leading the digital strategy for clinical, regulatory, safety and medical affairs. Prior to joining Moderna JR was at Vertex pharmaceuticals where he transformed Clinical IT into a technology technology team enabling drug development processes and supporting the approval of five innovative medicines. He is a strong believer that people should be the main driver for technology to “make easy things easy and hard things possible”. JR is passionate about delivering life changing therapies to patients in need.

Principal Investigator’s Perspective:

Sanjeev Bhavnani
Cardiologist & Principal Investigator, Scripps Health

Sanjeev Bhavnani MD is a cardiologist and physician-scientist in healthcare innovation and practice transformation at Scripps Clinic and Research Foundation. Dr. Bhavnani was a Qualcomm Wireless Health Scholar at TSRI where he was involved in the design of next generation digital medicine clinical trials. As a principle investigator on several studies, he has designed trials using nanosensors, wireless mHealth and smartphone-connected devices, handheld ultrasound, lab-on-a-chip technologies and cloud-based data platforms across various patient populations, and to assess the impact of new technologies on healthcare quality, costs, and outcomes. These trials have been executed across the US and in resource limited areas – Uganda, India, and Mexico – were he and his team have designed the first smartphone-connected mHealth clinics . To date, these mHealth clinics have enrolled 20,000+ patients. Dr. Bhavnani works with teams of clinicians, researchers, biomedical engineers, translational informatics, and biostatisticians. He serves on the innovation advisory boards of several national medical societies and has worked with digital health think tanks to develop the CONNECT legislation and 21st Century Cures Act. He is board certified in internal medicine, cardiovascular diseases, nuclear cardiology, echocardiography, and clinical informatics and has been recognized with a Health Catalyst Award and 40-under-40 life science innovators in San Diego.


Brad Pruitt
Executive Medical Director, Digital Health
PRA Health Sciences


Thursday, 13 August 2020
15:00 – 16:00 Singapore Standard Time (SST)

Re-writing the Optimised Clinical Trials Playbook

This bespoke digital theater takes place on Thursday 13th August 15:00-16:00 Singapore Standard Time (SST).   

The clinical trial environment was already evolving at a rapid pace before the presence of COVID-19, but now speed and efficiency are paramount. With a focus toward achieving faster time to market, reducing R&D costs, and increasing clinical trial success rates, various digital tools such as AI, machine learning, telemedicine are quickly becoming the next frontier in clinical studies.  

Alongside the case study sharing of these digital strategies, multiple illustrative examples will be used to present the practical considerations and execution of designing and running various adaptive design strategies, including logistics and impact on clinical operations, data management, and randomization services with focus on implications for statisticians.  

Conducted in the format of a fireside chat, in this session you will be able to gain insights into:  

  • Understanding the impact of today’s environment on clinical trials and their patients  
  • Collaboration and new business models  
  • Clinical study design thinking focus to reduce cost, accelerate speed to market and reduce regulatory burden  
  • Technology innovation for clinical trials – where do we stand?  
  • Critical steps of establishing an effective digital strategy  
  • Case study sharing and Q&A  

The Expert Panelists:



Dr. Chen Guang
Consultant and Clinical Diagnostics Technologist
Stronghold Diagnostic Lab – A*STAR, Singapore

Dr. Chen Guang obtained his Ph.D. in Coronavirology from National University of Singapore and has worked in different areas of bio pharmacology. He specialised in clinical research at Duke-NUS Graduate Medical School and Singapore General Hospital, and also has experience in the discovery and development phase at Simcere Pharmaceutical (an NYSE listed company); Dr. Chen is involved in biopharma investment and management. Dr. Chen is currently working on large scale diagnosis lab on COVID-19 at ASTAR.



Dr. Harish Dave
Co-founder and Chief Medical Officer, AUM Biosciences, Singapore

A Board-certified oncologist and hematologist with more than 35 years of experience, Dr. Harish Dave has conducted over 100 studies in hematology, oncology and transplantation. He has extensive experience in managing regulatory authorities including successful submission of over 50 INDs. Harish has also structured and executed a private equity Novaquest–sponsored strategic virtual drug development collaboration between Quintiles and Eisai, and has held various senior management positions at IQVIA, George Washington University Medical Center and VA Medical Center in Washington.



Dr. Tam C. Nguyen
Deputy Director of Research, St. Vincent’s Hospital Melbourne, Associate Professor, Melbourne Medical School, Adjunct Associate Professor, RMIT University, Australia

Associate Professor Tam Nguyen PhD MBA FRSPH FAIM MAICD is the Deputy Director of Research at St Vincent’s Hospital Melbourne responsible for research strategy, research business development and research administration. Tam leads a dynamic team dedicated to providing innovative solutions to facilitate health and medical research, which includes the Research Valet® Service, a rapid IRB service. His team leads the sector initiative in building the Victorian Clinical Trials Gateway™, a web portal with the support of the Victorian government aiming to attract new clinical trials to the state and Australia.



Dr. K. Arnold Chan
Director of Clinical Trial Center
National Taiwan University Hospital, Taiwan

Dr. Chan is a physician epidemiologist with more than 20 years of global research experience in academia and private sector, primarily on evaluation of pharmaceutical agents and vaccines. He has served on the faculty at National Taiwan University and Harvard School of Public Health, and returned to his alma mater (National Taiwan University) in 2013.

He has extensive experience in managing research organization and complex human research projects. In addition to scientific research, he has provided consulting input to Taiwan Food and Drug Administration and related health authority for more than 20 years. Dr. Chan has authored or co-authored more than 100 peer-reviewed articles on pharmacoepidemiology and clinical epidemiology. Along with Professor Abraham Hartzema and Professor Hugh Tilson, Dr. Chan co-edited one of the two widely used English textbook on pharmacoepidemiology.